Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex (ATTACK)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03894046 |
|
Recruitment Status :
Completed
First Posted : March 28, 2019
Results First Posted : February 1, 2023
Last Update Posted : February 1, 2023
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acinetobacter Baumannii-calcoaceticus Complex Hospital-acquired Bacterial Pneumonia Ventilator-associated Bacterial Pneumonia Bacteremia Colistin Resistant ABC | Drug: Sulbactam Drug: Durlobactam Drug: Colistin Drug: Imipenem/Cilastatin 500 mg/500 mg | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 207 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Masking Description: | Study drugs will not be masked due to logistical reasons, every attempt will be made to maintain the blind for patients, all staff at the site, and the Sponsor or its designees, except for the treatment physician and other immediate healthcare providers. |
| Primary Purpose: | Treatment |
| Official Title: | A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex |
| Actual Study Start Date : | September 5, 2019 |
| Actual Primary Completion Date : | July 26, 2021 |
| Actual Study Completion Date : | July 26, 2021 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Part A - Group 1
Part A was the pivotal, assessor-blind, randomized, comparative portion of the study in patients with documented ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), ventilated pneumonia (VP), or bacteremia. Part A - Group 1 (experimental): 1.0 g sulbactam/1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h |
Drug: Sulbactam
1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h). Drug: Durlobactam 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h). Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated. Other Name: ETX2514 Drug: Imipenem/Cilastatin 500 mg/500 mg 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated. |
|
Active Comparator: Part A - Group 2
Part A - Group 2 (control group): 2.5 mg/kg colistin IV infused over 30 minutes every 12 hours (after an initial loading dose of colistin 2.5 to 5 mg/kg) plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h.
|
Drug: Colistin
Treatment for 7 days up to 14 days if clinically indicated.
Other Name: COLOMYCIN INJECTION 2 million IU/vial Drug: Imipenem/Cilastatin 500 mg/500 mg 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated. |
|
Experimental: Part B - Group 3
Part B (Group 3) was the open-label, supportive portion of the study that included patients known to have HABP, VABP, VP, and/or bacteremia infections associated with ABC organisms resistant to colistin or polymyxin B, who failed a colistin or polymyxin B regimen prior to study entry or were on acute renal replacement therapy, and patients with infections due to colistin- or polymyxin B-resistant ABC with sources of infection other than HABP, VABP, VP, and/or bacteremia. Part B - Group 3: 1.0 g ETX2514/1.0 g sulbactam IV infused over 3 hours q6h plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. |
Drug: Sulbactam
1.0 g sulbactam IV infused over 3 hours every 6 hours (q6h). Drug: Durlobactam 1.0 g durlobactam IV infused over 3 hours every 6 hours (q6h). Sulbactam-Durlobactam: Treatment for 7 days up to 14 days if clinically indicated. Other Name: ETX2514 Drug: Imipenem/Cilastatin 500 mg/500 mg 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h. Treatment for 7 days up to 14 days if clinically indicated. |
- Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population [ Time Frame: 28 Days ]The primary efficacy endpoint for the study is 28-day all-cause mortality in the CRABC m-MITT population in Part A.
- Proportion of Patients With Nephrotoxicity [ Time Frame: 28 days ]The primary safety endpoint for the study is nephrotoxicity, as measured by the Risk-Injury-Failure-Loss-End-stage renal disease (RIFLE) criteria, in the MITT population in Part A.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
PART A
- A confirmed diagnosis of a serious infection that will require treatment with IV antibiotics;
-
A known infection caused by ABC (bacteremia, HABP, VABP, VP, cUTI or AP, or surgical or post-traumatic wound infections) as either a single pathogen or member of a polymicrobial infection based on evidence from culture or, if available, rapid diagnostic test from a sample collected within 72 hours prior to randomization (HABP/VABP/VP patients), AND 1 of the following:
- Has received no more than 48 hrs of potentially effective (ie, Gram negative coverage) antimicrobial therapy prior to the first dose of study drug;
- Is clinically failing prior treatment regimens
- APACHE II score 10 and 30 inclusive, or SOFA score between 7 and 11 inclusive, at time of diagnosis
- Expectation, in the judgment of the Investigator, that the patient will benefit from effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study
- Women of childbearing potential (ie, not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization. Participating women of childbearing potential must be willing to consistently use one highly effective method of contraception (ie, condom, combined oral contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized partner) from Screening until at least 30 days after administration of the last dose of study drug.
PART B
1. Has an infection (HABP, VABP, VP, bacteremia, cUTI, AP, or surgical or post-traumatic wound infections) caused by ABC organisms known to be resistant to colistin (defined as MIC ≥4 mg/L by a non-agar based method);
- Known to be resistant to colistin or polymyxin B; or
- Known intolerance to colistin; or
- Has myasthenia gravis or another neuromuscular syndrome(s) that contraindicates colistin and is not ventilated; or
- Has acute kidney injury and is receiving renal replacement therapy at study entry.
Exclusion Criteria:
- Evidence of active concurrent pneumonia requiring additional antimicrobial treatment
- Presence of suspected or confirmed deep seated bacterial infections such as bacterial Gram negative osteomyelitis, endocarditis, or meningitis requiring prolonged therapy, as determined by history and/or physical examination;
- Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) ≥ 60 mmHg;
- Pregnant or breastfeeding women;
- Receiving peritoneal dialysis;
- Requirement for continuing treatment with probenecid, methotrexate, ganciclovir, valproic acid, or divalproex sodium during the study;
- Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis, hepatic cirrhosis, hepatic failure, chronic ascites, or hepatic encephalopathy;
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03894046
Show 92 study locations
Documents provided by Entasis Therapeutics:
| Responsible Party: | Entasis Therapeutics |
| ClinicalTrials.gov Identifier: | NCT03894046 |
| Other Study ID Numbers: |
CS2514-2017-0004 |
| First Posted: | March 28, 2019 Key Record Dates |
| Results First Posted: | February 1, 2023 |
| Last Update Posted: | February 1, 2023 |
| Last Verified: | January 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Pneumonia Bacteremia Pneumonia, Bacterial Acinetobacter Infections Infections Respiratory Tract Infections Lung Diseases Respiratory Tract Diseases Bacterial Infections Bacterial Infections and Mycoses Sepsis Systemic Inflammatory Response Syndrome Inflammation Pathologic Processes |
Moraxellaceae Infections Gram-Negative Bacterial Infections Imipenem Colistin Sulbactam Durlobactam Cilastatin Anti-Bacterial Agents Anti-Infective Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action beta-Lactamase Inhibitors |